Medical Oncologist
Medicines
How much does pertuzumab actually help? The numbers explained
Pertuzumab is added to trastuzumab for HER2-positive breast cancer, but how much it helps varies. The largest benefit is as a first treatment for advanced cancer, where it helped people live longer. In early cancer the extra benefit is more modest and mainly seen in higher-risk, node-positive disease. This page explains the evidence in plain terms.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How much does pertuzumab actually help?
- Where pertuzumab is used and what it adds
- Research terms and what they mean for you
- The vocabulary, in plain language
- Honest limits of the numbers
- Benefit, side effects and cost together
- Questions that help you understand your benefit
- What people assume about pertuzumab's benefit
- Common questions about the benefit of pertuzumab
The short answer
How much does pertuzumab actually help?
Pertuzumab, sold as Perjeta, is a HER2 antibody given together with trastuzumab, and usually chemotherapy, for HER2-positive breast cancer. How much it adds depends a great deal on the situation. The clearest benefit is in advanced HER2-positive breast cancer treated for the first time. In a large study, adding pertuzumab to trastuzumab and docetaxel chemotherapy kept the cancer controlled for longer and helped people live longer, on average by more than a year. That is a substantial benefit and is why this combination became a standard first treatment in many countries. In early breast cancer the picture is more modest. Given before surgery, pertuzumab increases the chance that no invasive cancer is left at the operation. Given after surgery, a large study found it lowered the chance of the cancer coming back, but the overall difference was small. The benefit was concentrated in people with cancer in the lymph nodes, where a few fewer people in every hundred had a recurrence. For people without lymph node involvement, the extra benefit after surgery was very small. This is why many teams use pertuzumab after surgery mainly for higher-risk cancers. Pertuzumab also adds side effects, especially diarrhoea, and cost. Understanding the size of the benefit in your own situation helps you and your oncologist weigh these factors together.
Largest benefit in advanced cancer
As a first treatment for advanced HER2-positive cancer, it helped people live longer on average.
Smaller benefit in early cancer
After surgery, the added reduction in recurrence was modest and mostly seen in higher-risk cancers.
Your risk shapes the value
The higher your risk of recurrence, the more there is to gain from adding it.
This page summarises research in general terms. It cannot predict what pertuzumab will do for you. Your oncologist can explain your own situation.Four situations
Where pertuzumab is used and what it adds
The same medicine can offer very different benefit depending on when it is used.
Before surgery
With trastuzumab and chemotherapy, it raises the chance of a complete response, where no invasive cancer is found at surgery.
After surgery, node-positive
It modestly lowers the chance of recurrence. This is where the benefit after surgery was clearest.
The absolute gain is a few people in every hundred.After surgery, node-negative
The added benefit was very small, so many teams do not routinely add pertuzumab here.
Advanced cancer, first treatment
Added to trastuzumab and docetaxel, it controlled cancer for longer and improved survival.
What this meant in the study
- Longer time before the cancer grew
- Longer survival on average
- Benefit maintained over long follow-up
Reading the numbers
Research terms and what they mean for you
Term in studies
What it means in plain language
Pathological complete response
No invasive cancer left in the breast and nodes at surgery
Invasive disease-free survival
Being alive without the cancer returning or a new invasive cancer
Progression-free survival
How long advanced cancer stays controlled without growing
Overall survival
How long people live, whatever the cause
Absolute benefit
How many people out of a hundred actually gain from treatment
Words you will hear
The vocabulary, in plain language
- Dual HER2 blockade
- Using pertuzumab and trastuzumab together, which attach to different parts of HER2.
- Neoadjuvant
- Treatment given before surgery.
- Adjuvant
- Treatment given after surgery to lower the chance of recurrence.
- Node-positive
- Cancer found in the lymph nodes under the arm, which raises the risk of recurrence.
- Relative risk reduction
- The percentage by which a treatment lowers risk, which can sound large even when the real gain is small.
- Median
- The middle value in a group. Half the people did better and half did less well.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Honest limits of the numbers
Study results are the best guide available, but they describe groups of people, not individuals.
Averages hide wide variation
Some people gain a lot from pertuzumab, and some gain nothing. No test can yet tell which group you are in.
Treatment has moved on
Studies were run years ago. Today's other treatments, such as T-DM1 for cancer left after surgery, may change how much pertuzumab adds.
A complete response is encouraging, not conclusive
A higher chance of no cancer at surgery is encouraging, but it does not by itself prove a longer life for every person.
What this page cannot tell you
It cannot calculate your personal benefit. Your oncologist can use your tumour size, nodes and other features to estimate it.
Weighing it up
Benefit, side effects and cost together
Deciding about pertuzumab means weighing what it adds against what it asks of you. There is no single right answer for everyone.
Side effects
Diarrhoea is the main extra side effect, especially during chemotherapy. Rash and tiredness are also reported. Heart problems do not appear to be much more common than with trastuzumab alone.
Cost
Pertuzumab adds significant cost to HER2 treatment in India. When the expected benefit is small, cost may reasonably weigh more heavily in the decision.
Your priorities
Some people want every possible gain, however small. Others prefer to avoid extra side effects and expense. Both are valid choices to discuss openly.
Talking to your oncologist
Questions that help you understand your benefit
These questions turn general numbers into something meaningful for you.
About your risk
What is my estimated chance of recurrence with trastuzumab alone, and how much would adding pertuzumab lower it, in people out of a hundred?
About the timing
Is pertuzumab recommended before surgery, after surgery, or both, and why for my cancer?
About alternatives
If cost or side effects are a problem, what would the plan look like without pertuzumab?
Commonly believed
What people assume about pertuzumab's benefit
Adding a second antibody doubles the benefit.
The extra gain varies widely and in early cancer it is usually modest.
Everyone with HER2-positive cancer needs pertuzumab.
Its value depends on stage and risk; some people gain very little from it.
Without pertuzumab, HER2 treatment will not work.
Trastuzumab with chemotherapy is effective on its own for many people.
A large percentage reduction always means a large gain.
Relative figures can sound big; the number of people who actually benefit matters more.
Questions we are asked
Common questions about the benefit of pertuzumab
Does pertuzumab help people live longer?
In advanced HER2-positive breast cancer treated for the first time, yes: a large study showed longer survival on average when pertuzumab was added. In early breast cancer, it lowers the chance of recurrence, but a clear difference in overall survival after surgery has been harder to show.
Why is pertuzumab given before surgery?
With trastuzumab and chemotherapy, it increases the chance of shrinking the cancer completely before the operation. This can make surgery easier and gives useful information: if cancer remains, your team may switch to T-DM1 afterwards to lower the risk of recurrence.
My nodes were clear. Do I need pertuzumab after surgery?
For many people with node-negative cancer, the extra benefit after surgery is very small, and trastuzumab alone is often considered enough. Your oncologist will look at tumour size, grade, hormone status and any treatment before surgery before making a recommendation.
How much does it lower recurrence if my nodes were positive?
In the main study, a few fewer people in every hundred with node-positive cancer had their cancer return over several years when pertuzumab was added. Your own benefit may be higher or lower, depending on how many nodes were involved and other features of your cancer.
Is pertuzumab useful after advanced cancer has already grown on HER2 treatment?
Its proven benefit is mainly as part of the first treatment for advanced cancer. Once cancer has grown despite HER2 treatment, other medicines such as trastuzumab deruxtecan or T-DM1 are usually considered instead. Your team will explain the options available at that stage.
Is there a test that shows who benefits most?
Not yet. Being HER2-positive is required, and higher-risk features such as positive nodes point to more benefit in early cancer. Research is looking for better markers, but for now decisions rely on stage, risk and your preferences.
Does pertuzumab add much to side effects?
The main addition is diarrhoea, which is most noticeable during chemotherapy and often eases afterwards. Rash, tiredness and mouth soreness can also increase. Heart problems do not appear to be much more common than with trastuzumab alone, but heart scans continue.
Is it reasonable to decide against pertuzumab?
Yes, in some situations. When the expected benefit is small, choosing trastuzumab without pertuzumab can be a reasonable, informed decision. Discuss it openly with your oncologist, who can explain what you might give up and whether it matters for your cancer.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- National Cancer Institute — Pertuzumab
- European Medicines Agency — Perjeta: product information
- Cancer Research UK — Pertuzumab (Perjeta)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.